Trans-Doxercalciferol is marketed in two principal dosage forms—oral capsules and injectable solutions—each with distinct pharmacokinetic profiles and supply‑chain implications. The oral capsule, typically a 0.25 µg or 0.5 µg tablet, dominates the market due to patient convenience, lower manufacturing complexity, and broader distribution through retail pharmacies. It accounts for approximately 70 % of total sales, reflecting higher prescription volumes and longer treatment cycles. Injectable formulations, administered intravenously during dialysis sessions, represent the remaining 30 % and are preferred in settings where rapid serum‑phosphate control is critical. Although the injectable segment incurs higher production costs and requires cold‑chain logistics, it commands premium pricing and is essential for patients with severe secondary hyperparathyroidism who cannot achieve target levels with oral therapy alone. The bifurcation by type therefore delineates cost structures, adoption barriers, and growth trajectories within the Trans‑Doxercalciferol market, with oral products driving volume and injectables contributing margin expansion. Future shifts toward home‑based dialysis could elevate injectable uptake, potentially narrowing the current disparity between the two formats.
